Mirum Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost
Mirum Pharmaceuticals, Inc. (MIRM) had Debt Securities, Available-for-sale, Amortized Cost of $493.74 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $493.74M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $357.25M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $348.99M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $493.74M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $357.25M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $348.99M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |